Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant dovitinib before local treatment for hepatocellular carcinoma
NL-OMON35941Phase 2Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in hepatocellular carcinoma (HCC), sponsored by Leiden University Medical Center. Primary endpoints: Toxicity and safety, Tumor response by RECIST and CT perfusion and 1 more. Started May 2012; status: active, not recruiting.
02
Drugs
dovitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON35941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35941.